The erectile dysfunction and FSAD symptoms have been alleviated by PT-141 Peptide, commonly known as Bremelanotide. PT-141’s peptide structure makes it a potentially safer substitute for PDE5 medications like Viagra and Cialis.
For further details, see the description below or check out the PT-141 reviews for feedback from actual customers. Put some PT-141 peptides in your virtual shopping basket if you’re eager to maximize their potential in research. You can find PT-141 for sale if you are a licensed professional looking further to expand the field of information available on this topic.
What exactly is PT-141?
Initially, PT-141 was studied for its possible use in fake tanning. Interestingly, previous to the development of the PT 141 peptide, two additional peptides, Melanotan I and II, were created with this goal in mind. Melanotan II became the sought-after tanning agent, but it also had another valuable property. Bremelanotide was developed because of its beneficial effect on sexual dysfunction.
You won’t want to try anything else to improve your subjects’ sexual performance after using PT 141, also known as Bremelanotide and Vyleesi. It is a peptide, making it distinct from many other chemicals on the market, such as Cialis and Viagra. Since the body already makes peptides, manufactured versions have fewer adverse effects and work well with the body. The PT 141 peptide is a cyclic sequence of seven amino acids, including an amide group.
It acts as an agonist on all melanocortin receptors, including MC1 through MC5. Except for the MC2 receptor, all other receptors are impacted by PT-141. MC4 controls sexual behavior, whereas other receptors like MC1 and MC3 are responsible for skin color and homeostasis.
Issues of Sexual Dysfunction and PT-141
You may wonder whether PT 141 peptide is a good option for your research. In truth, there are three inquiries you need to make of yourself. These three questions are, first, whether or not your subjects can get an erection on their own. Second, whether or not they have trouble finishing (i.e., ejaculating), and third, whether or not their body can physically support an erection for a more extended period. If you replied “no” to any of these questions, you should consider administering PT-141 to your test subjects.
PT-141 has been shown to help males with erectile dysfunction and related issues, such as premature ejaculation. Sexual dysfunction may manifest itself in a variety of ways in females. Female-specific arousal deficiency (also known as hypoactive sex desire disorder) is one such route (HSDD). Both of these conditions may exist simultaneously in females. But PT-141 may help subjects overcome these issues and get their sex life back on track.
Bremelanotide was used in clinical research to treat 293 females with one or both conditions. The females before menopause were split into four groups, each receiving a slightly different dosage. The statistical and clinical gains were most prominent among the females who received 1.25mg to 1.75mg of PT-141 compared to the other groups. This means that PT 141 peptide may be used to treat females with HSDD or FSAD.
Adverse Reactions to PT-141
There are various potential negative consequences of PT 141 peptide. Nausea is a typical complaint among those who take PT 141 peptide. Using an anti-nausea medicine before peptide administration may help avoid or lessen the severity of nausea. Flushing, headache, vomiting, exhaustion, heat flashes, dizziness, and coughing are some additional, less prevalent adverse effects.
Hyperpigmentation is a possible Bremelanotide adverse effect. The gums, cheeks, and breasts are the most common areas where this darkening occurs.
There have been reports of PT-141 causing a rise in blood pressure; thus, those with high blood pressure or cardiovascular disease may wish to avoid it. It is not recommended to use the PT-141 peptide if subjects are also taking other resembling medications due to the risk of an adverse response. Oral absorption of other substances has also been shown to be reduced by this compound.
